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Introduction. Neoadjuvant chemoradiotherapy for locally advanced rectal cancer has been shown to decrease rates of local recur-
rence. There is now compelling evidence that pathological complete response is an independent predictor of local recurrence,
distal metastases, disease-free and overall survival .The purpose of this review is to highlight tumour regression grading in our
patients with rectal cancer.
Methods. From 2010 to 2012 120 patients were treated in our institution with rectal cancer, only 76 of them were eligible for this
study. All of them were treated with long-course neoadjuvant chemoradiation. Patients received different 5FU based chemother-
apy regimens. Radiation therapy was administrated to the pelvic volume to a dose of 45Gy and boost over primary tumor of
5.4Gy (total dose to 50.4Gy) employing 3D-CRT. We used Dworak tumor regression system for rectal cancer.
Results. All patients have completed neoadjuvant treatment and underwent surgical procedures. 30% of patients had complete
response in the bowel wall (ypT0). Of the remaining 51 patients who had residual cancer cells, 35.5% were Gr3, 16.5% were GR2,
16.5% were GR1, only one patient were GR0. With a follow up of 20 months 88% patients are DFS, 9% have developed distant
metastases and 1.3% (1 patient) have developed local recurrence.
Conclusion. This study demonstrates the feasibility of preoperative chemoradiotherapy with a high pCR rate, comparable with
previously reported. Longer follow-up is needed to analyze if the regression degree has inﬂuence on DFS and OS.
http://dx.doi.org/10.1016/j.rpor.2013.03.217
Rectal cancer in hospital Carlos Haya, Malaga. Preoperative radiochemotherapy
A. Ramos Trujillo, L. Hebrero Jimenez, I. Herruzo Cabrera, A. Slocker Espcarpa, R. Delgado Rico, L. Garcia Sanchez,
I. Fortes de La Torre, J. Contreras Martinez, J. Villén Villén
Complejo Hospitalario Carlos Haya, Oncología Radioterápica, Spain
Introduction. Total mesorectal excision (TME) decreases local recurrence of rectal cancer, and preoperative radiotherapy is also
beneﬁcial for local control.Weevaluate the results after the combinedpreoperative treatment inpatients (p)with locally advanced
resectable rectal cancer treated in our hospital.
Objective. We have analysed 161 p with rectal cancer T3–T4 (assessed by endoanal ultrasound CT and in later years MRI)
treated with RT3DC (45–50.4Gy/1.8Gy fraction) and concomitant chemotherapy with (Xeloda 850mg/daily in 53.4% or Tega-
fur 1200mg/daily in 38.5%), followed by surgery after 6–8 weeks. Later on 70.2% received adjuvant chemotherapy based on XELOX
(Xeloda/IMPACT/FOLFOX/De Gramont/Mayo/5-FU+AF) iv according to protocol.
Materials and methods. From January 2003 to December 2010 we treated 108 men and 53 women. Median age 66 years (range 27-80)
Initial state: uT3: 146 p/uT4: 13 p/N+: 49 (30.4%). Tumor <6 cm from the anal margin, 77 p (47.8%), >6 cm 81 (50.3%). The surgery
consisted of: abdominoperineal resection 71 p (44.1%), (anterior) resection 79 p (47.8%), endoanal resection 1 p (0.6), and exclusive
colostomy by frozen pelvis 1 p (0.6). We did not record a signiﬁcant increase in complications occurring during surgery. We
obtained a “downstaging” of tumors in 88 p (54.7%) including 25 p (15.5%) with pathological complete response. The post surgery
pathologic anatomy was 50.9% well-differentiated adenocarcinoma, 25.5% moderately differentiated, 9% undifferentiated. There
was locoregional recurrence in 9 p, and 19 p have relapsed with time. Of them 119 p remain disease free, 9 live with the illness,
10 died of other causes, and 17 died of recurrence. Overall survival has been 78,6% with an actuarial follow up of 114 months.
The survival free of recurrence has been 67.8% with an actuarial follow up of 117 months.
Conclusions. Preoperative radiochemotherapy increases the local control with amanageable toxicity proﬁle, obtaining good results
and diminution of previous stage and surgery and also survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.218
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Introduction. The management of rectal cancer has undergone a radical change during the last years. Several studies have
shown a reduction in recurrence and toxicity in patients treated with concomitant preoperative chemoradiotherapy compared
to postoperative treatment, as well as a survival increased.
Objective. To analyze the results of our experience in the treatment of rectal cancer stage II and III with neoadjuvant chemora-
diotherapy, to know the efﬁciency in terms of toxicity, recurrence and survival.
